ENHANCING NEUROPLASTICITY AND COGNITIVE FUNCTION IN AGING ADULTS USING IV UMBILICAL CORD STEM CELLS COMBINED WITH NAD+ THERAPY

Did your incompetent? doctor DO NOTHING with this earlier research?

NAD (2 posts to May 2014)

Has your incompetent board of directors not fired your doctor yet? Is 10 years of incompetence not enough to prove incompetence?

 ENHANCING NEUROPLASTICITY AND COGNITIVE FUNCTION IN
AGING ADULTS USING IV UMBILICAL CORD STEM CELLS COMBINED
WITH NAD+ THERAPY

Author: Samuel Omoleye

Abstract

Cognitive decline is a prominent concern among aging adults, often linked to

diminished neuroplasticity and cellular degeneration within the brain. Conventional

treatments provide limited efficacy and do not address the underlying cellular

mechanisms driving age-related cognitive deterioration. This study explores the

synergistic effects of intravenous (IV) umbilical cord-derived mesenchymal stem cells

(UC-MSCs) and nicotinamide adenine dinucleotide (NAD+) therapy as a novel

regenerative approach to enhance neuroplasticity and cognitive function in elderly

individuals. A controlled clinical design involving aging participants received a

combined protocol of UC-MSC infusion and NAD+ supplementation over a defined

treatment period. Cognitive performance was assessed through standardized

neuropsychological tests, while biomarkers of neurogenesis and synaptic plasticity

were evaluated using imaging and molecular assays. Preliminary findings indicate

significant improvements in memory, attention, and executive function, alongside

increased markers of synaptic density and neurotrophic support. These results suggest

that the integration of stem cell therapy with NAD+ holds promise as a viable

intervention for mitigating cognitive decline and promoting brain rejuvenation in

older adults. Further large-scale studies are recommended to validate the long-term

efficacy and safety of this combinational treatment.

Keywords: Neuroplasticity,Cognitive Decline, Aging Adults; Umbilical Cord Stem

Cells, NAD+ Therapy, Intravenous Stem Cell Therapy,

1. Introduction

The global population is aging at an unprecedented rate, leading to a sharp increase in

age-related cognitive disorders such as mild cognitive impairment (MCI),

Alzheimer’s disease, and other forms of dementia. These conditions not only reduce

the quality of life for aging individuals but also pose significant social and economic

burdens. One of the key contributors to cognitive decline is the progressive loss of

neuroplasticity—the brain’s ability to reorganize, form new neural connections, and

adapt in response to experience or injury. As individuals age, synaptic connectivity

and neurogenesis decrease, resulting in impaired learning, memory, and executive

functioning.

Traditional pharmaceutical approaches to cognitive decline offer limited relief, often

targeting symptoms rather than underlying neurobiological dysfunctions.

Consequently, there is growing interest in regenerative medicine and cellular

therapies that aim to reverse or slow these processes at a more fundamental level.

Among these, umbilical cord-derived mesenchymal stem cells (UC-MSCs) have

gained considerable attention due to their immunomodulatory properties, low

immunogenicity, and potential to secrete neurotrophic factors that enhance neural

repair and regeneration. In parallel, nicotinamide adenine dinucleotide (NAD+), a

vital coenzyme involved in cellular metabolism and DNA repair, has emerged as a

promising candidate for neuroprotective therapy. NAD+ levels naturally decline with

age, contributing to mitochondrial dysfunction and neurodegeneration.

Supplementation with NAD+ precursors has demonstrated benefits in improving

neuronal function, reducing inflammation, and enhancing cognitive performance in

preclinical and early clinical studies.

More at link.